Windlas Biotech Limited (NSE:WINDLAS)
India · Delayed Price · Currency is INR 871.00
-29.40 (-3.27%)
Oct 23, 2026, 3:29 PM IST
Windlas Biotech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 17,974 | 15,529 | 21,747 | 10,614 | 4,715 | 4,578 | |
Market Cap Growth | -9.86% | -28.59% | 104.90% | 125.11% | 2.99% | - |
Enterprise Value | 15,538 | 13,235 | 19,806 | 8,990 | 2,946 | 2,605 |
Last Close Price | 900.40 | 731.23 | 1026.21 | 500.17 | 218.56 | 200.78 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 27.98 | 23.37 | 35.65 | 18.24 | 11.06 | 12.02 |
PS Ratio | 1.97 | 1.72 | 2.86 | 1.68 | 0.92 | 0.98 |
PB Ratio | 3.20 | 2.67 | 4.30 | 2.36 | 1.17 | 1.16 |
P/TBV Ratio | 3.24 | 2.71 | 4.36 | 2.38 | 1.18 | 1.16 |
P/FCF Ratio | 49.85 | 41.67 | 135.98 | 14.89 | - | - |
P/OCF Ratio | 17.71 | 14.80 | 31.89 | 9.74 | 7.73 | 50.14 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.71 | 1.46 | 2.61 | 1.43 | 0.57 | 0.56 |
EV/EBITDA Ratio | 15.45 | 13.13 | 21.77 | 11.80 | 5.02 | 5.05 |
EV/EBIT Ratio | 21.70 | 17.89 | 29.79 | 13.89 | 6.15 | 6.47 |
EV/FCF Ratio | 43.32 | 35.51 | 123.84 | 12.61 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.34 | 0.34 | 0.35 | 0.05 | 0.08 | 0.13 |
Debt / FCF Ratio | - | 0.95 | 2.04 | 0.05 | - | - |
Net Debt / Equity Ratio | -0.42 | -0.42 | -0.41 | -0.45 | -0.32 | -0.43 |
Net Debt / EBITDA Ratio | -2.39 | -2.42 | -2.27 | -2.63 | -2.16 | -3.29 |
Net Debt / FCF Ratio | - | -6.53 | -12.92 | -2.82 | 12.79 | 29.85 |
Asset Turnover | - | 1.08 | 1.10 | 1.09 | 1.01 | 1.18 |
Inventory Turnover | - | 7.84 | 6.61 | 5.85 | 4.94 | 6.15 |
Quick Ratio | - | 1.58 | 1.64 | 1.99 | 2.06 | 3.08 |
Current Ratio | - | 1.95 | 2.11 | 2.51 | 2.92 | 4.06 |
Return on Equity (ROE) | - | 12.23% | 12.76% | 13.66% | 10.70% | 12.83% |
Return on Assets (ROA) | - | 5.55% | 5.99% | 7.00% | 5.87% | 6.40% |
Return on Invested Capital (ROIC) | 16.91% | 17.77% | 18.55% | 18.63% | 14.29% | 16.73% |
Return on Capital Employed (ROCE) | - | 12.60% | 13.00% | 14.20% | 11.70% | 10.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.57% | 4.28% | 2.80% | 5.48% | 9.04% | 8.32% |
FCF Yield | 2.01% | 2.40% | 0.73% | 6.72% | -2.10% | -1.24% |
Dividend Yield | 0.72% | 0.86% | 0.56% | 1.08% | 1.78% | 1.67% |
Payout Ratio | 20.24% | 18.29% | 18.85% | 14.27% | 17.89% | - |
Buyback Yield / Dilution | -0.72% | -0.98% | -1.22% | 3.53% | -5.56% | -12.58% |
Total Shareholder Return | -0.03% | -0.12% | -0.66% | 4.61% | -3.78% | -10.91% |